Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy

NCT05399641 is registered in ClinicalTrials.gov with Scynexis, Inc. as lead sponsor.

NCT NCT05399641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy
Lead sponsor
Scynexis, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 1, 2022
Completion date
August 2, 2023
Enrollment
150 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

vulvovaginal candidiasis